Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) announced that it would be launching a special access psychedelic-assisted psychotherapy program, called the Special Access Support and Supply Program. The program will be available to patients who require alternative treatment modalities in Canada. The country recently added psilocybin and MDMA to its Special Access Program.
Mydecine’s objective is to change the way in which mental health conditions and addiction disorders are treated. The company will provide support services through the program, which will play an important role in fulfilling the company’s mission statement. This is in addition to offering specialized psychedelic therapy products to physicians, clinics and hospitals in various parts of Canada.
In a public statement about the program, Mydecine chief medical officer Dr. Rakesh Jetly stated that the company recognized that there were patients suffering from mental health indications who hadn’t responded to evidence-based treatments and the company was committed to demonstrating the effectiveness and safety of psychedelic medicines for certain indications through its clinical trials.
He added that he believed Mydecine’s program could help treat a substantial patient population in need of alternative options, noting that the company’s team of doctors, researchers and advisors had significant experience in administering these treatments and looked forward to sharing that expertise and knowledge to promote the successful and responsible use of MDMA and psilocybin.
The company’s news closely follows a Health Canada announcement that amended government regulations, thereby allowing practitioners and pharmacists to request psilocybin and MDMA for patients who haven’t benefitted from other treatment modalities. Mydecine’s program will set the stage for practitioners to acquire a package that contains protocol training, advisory services, therapy manuals, psilocybin and MDMA, post-therapy support and investigative brochures. These services and products will be offered through Mydecine subsidiary Mindleap Health.
The company’s CEO Josh Bartch stated that the objective of the Special Access Support and Supply Program was to help physicians who believed that the use of alternative treatments such as psilocybin and MDMA would assist patients in overcoming addiction and mental health challenges. Currently, the company is producing psychedelics through the Schedule 1 Drugs/Substance license as well as carrying out a number of clinical trials that are evaluating the effectiveness of psychedelic compounds as treatment modalities. The company also has a partnership with Johns Hopkins University.
While there’s no guarantee that a similar program will be launched in other countries, the launch of the Special Access Support and Supply Program in Canada is an optimistic indicator for shareholders of the psychedelic company.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
